Blasts in CSF with a normal cell count do not justify alteration of therapy for acute lymphoblastic leukemia in remission

A Childrens Cancer Group study

D. G. Tubergen, J. W. Cullen, J. M. Boyett, G. S. Gilchrist, R. T. O'Brien, Peter Felix Coccia, M. J. Waskerwitz

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Purpose: The Childrens Cancer Group (CCG) requires both a CSF WBC count of more than five cells per microliter and demonstration of blast cells in the cytocentrifuge specimen to support a diagnosis of CNS relapse. We reviewed the CSF examinations of patients with intermediate-risk acute lymphoblastic leukemia (ALL) to determine the clinical significance of blast cells reported in the cytocentrifuge when the total CSF cell count was normal. Patients and Methods: Children treated on CCG-105 for ALL had CSF examinations every 12 weeks during maintenance therapy. The outcome of children who had a positive CSF cytocentrifuge examination without an elevated CSF WBC count was compared with that of children who did not have any CSF blast cells observed. Results: Sixty-four patients had 81 CSF examinations with blast cells and a normal cell count. By Cox life-table regression analysis, patients with blasts had a different disease-free survival (DFS) distribution, with relapses tending to occur earlier (P = .008). However, the DFS for these patients was 63% ± 9.6% at 5 years from the time of the abnormal cytocentrifuge result as compared with 69% ± 1.5% for 1,490 children who did not have blasts in their CSF. This difference is not significant. Conclusion: Blast cells were infrequently identified in cytocentrifuge preparations of CSF when the cell count was normal. The majority of patients in whom such an event was observed have not experienced a subsequent relapse as measured by life-table analysis at 5 years. The data do not justify changing or augmenting therapy based on cytocentrifuge results alone.

Original languageEnglish (US)
Pages (from-to)273-278
Number of pages6
JournalJournal of Clinical Oncology
Volume12
Issue number2
DOIs
StatePublished - Jan 1 1994

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Cell Count
Neoplasms
Life Tables
Recurrence
Disease-Free Survival
Therapeutics
Regression Analysis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Blasts in CSF with a normal cell count do not justify alteration of therapy for acute lymphoblastic leukemia in remission : A Childrens Cancer Group study. / Tubergen, D. G.; Cullen, J. W.; Boyett, J. M.; Gilchrist, G. S.; O'Brien, R. T.; Coccia, Peter Felix; Waskerwitz, M. J.

In: Journal of Clinical Oncology, Vol. 12, No. 2, 01.01.1994, p. 273-278.

Research output: Contribution to journalArticle

Tubergen, D. G. ; Cullen, J. W. ; Boyett, J. M. ; Gilchrist, G. S. ; O'Brien, R. T. ; Coccia, Peter Felix ; Waskerwitz, M. J. / Blasts in CSF with a normal cell count do not justify alteration of therapy for acute lymphoblastic leukemia in remission : A Childrens Cancer Group study. In: Journal of Clinical Oncology. 1994 ; Vol. 12, No. 2. pp. 273-278.
@article{cb1c84a4fd634e7ea03574d710a89734,
title = "Blasts in CSF with a normal cell count do not justify alteration of therapy for acute lymphoblastic leukemia in remission: A Childrens Cancer Group study",
abstract = "Purpose: The Childrens Cancer Group (CCG) requires both a CSF WBC count of more than five cells per microliter and demonstration of blast cells in the cytocentrifuge specimen to support a diagnosis of CNS relapse. We reviewed the CSF examinations of patients with intermediate-risk acute lymphoblastic leukemia (ALL) to determine the clinical significance of blast cells reported in the cytocentrifuge when the total CSF cell count was normal. Patients and Methods: Children treated on CCG-105 for ALL had CSF examinations every 12 weeks during maintenance therapy. The outcome of children who had a positive CSF cytocentrifuge examination without an elevated CSF WBC count was compared with that of children who did not have any CSF blast cells observed. Results: Sixty-four patients had 81 CSF examinations with blast cells and a normal cell count. By Cox life-table regression analysis, patients with blasts had a different disease-free survival (DFS) distribution, with relapses tending to occur earlier (P = .008). However, the DFS for these patients was 63{\%} ± 9.6{\%} at 5 years from the time of the abnormal cytocentrifuge result as compared with 69{\%} ± 1.5{\%} for 1,490 children who did not have blasts in their CSF. This difference is not significant. Conclusion: Blast cells were infrequently identified in cytocentrifuge preparations of CSF when the cell count was normal. The majority of patients in whom such an event was observed have not experienced a subsequent relapse as measured by life-table analysis at 5 years. The data do not justify changing or augmenting therapy based on cytocentrifuge results alone.",
author = "Tubergen, {D. G.} and Cullen, {J. W.} and Boyett, {J. M.} and Gilchrist, {G. S.} and O'Brien, {R. T.} and Coccia, {Peter Felix} and Waskerwitz, {M. J.}",
year = "1994",
month = "1",
day = "1",
doi = "10.1200/JCO.1994.12.2.273",
language = "English (US)",
volume = "12",
pages = "273--278",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "2",

}

TY - JOUR

T1 - Blasts in CSF with a normal cell count do not justify alteration of therapy for acute lymphoblastic leukemia in remission

T2 - A Childrens Cancer Group study

AU - Tubergen, D. G.

AU - Cullen, J. W.

AU - Boyett, J. M.

AU - Gilchrist, G. S.

AU - O'Brien, R. T.

AU - Coccia, Peter Felix

AU - Waskerwitz, M. J.

PY - 1994/1/1

Y1 - 1994/1/1

N2 - Purpose: The Childrens Cancer Group (CCG) requires both a CSF WBC count of more than five cells per microliter and demonstration of blast cells in the cytocentrifuge specimen to support a diagnosis of CNS relapse. We reviewed the CSF examinations of patients with intermediate-risk acute lymphoblastic leukemia (ALL) to determine the clinical significance of blast cells reported in the cytocentrifuge when the total CSF cell count was normal. Patients and Methods: Children treated on CCG-105 for ALL had CSF examinations every 12 weeks during maintenance therapy. The outcome of children who had a positive CSF cytocentrifuge examination without an elevated CSF WBC count was compared with that of children who did not have any CSF blast cells observed. Results: Sixty-four patients had 81 CSF examinations with blast cells and a normal cell count. By Cox life-table regression analysis, patients with blasts had a different disease-free survival (DFS) distribution, with relapses tending to occur earlier (P = .008). However, the DFS for these patients was 63% ± 9.6% at 5 years from the time of the abnormal cytocentrifuge result as compared with 69% ± 1.5% for 1,490 children who did not have blasts in their CSF. This difference is not significant. Conclusion: Blast cells were infrequently identified in cytocentrifuge preparations of CSF when the cell count was normal. The majority of patients in whom such an event was observed have not experienced a subsequent relapse as measured by life-table analysis at 5 years. The data do not justify changing or augmenting therapy based on cytocentrifuge results alone.

AB - Purpose: The Childrens Cancer Group (CCG) requires both a CSF WBC count of more than five cells per microliter and demonstration of blast cells in the cytocentrifuge specimen to support a diagnosis of CNS relapse. We reviewed the CSF examinations of patients with intermediate-risk acute lymphoblastic leukemia (ALL) to determine the clinical significance of blast cells reported in the cytocentrifuge when the total CSF cell count was normal. Patients and Methods: Children treated on CCG-105 for ALL had CSF examinations every 12 weeks during maintenance therapy. The outcome of children who had a positive CSF cytocentrifuge examination without an elevated CSF WBC count was compared with that of children who did not have any CSF blast cells observed. Results: Sixty-four patients had 81 CSF examinations with blast cells and a normal cell count. By Cox life-table regression analysis, patients with blasts had a different disease-free survival (DFS) distribution, with relapses tending to occur earlier (P = .008). However, the DFS for these patients was 63% ± 9.6% at 5 years from the time of the abnormal cytocentrifuge result as compared with 69% ± 1.5% for 1,490 children who did not have blasts in their CSF. This difference is not significant. Conclusion: Blast cells were infrequently identified in cytocentrifuge preparations of CSF when the cell count was normal. The majority of patients in whom such an event was observed have not experienced a subsequent relapse as measured by life-table analysis at 5 years. The data do not justify changing or augmenting therapy based on cytocentrifuge results alone.

UR - http://www.scopus.com/inward/record.url?scp=0028012394&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028012394&partnerID=8YFLogxK

U2 - 10.1200/JCO.1994.12.2.273

DO - 10.1200/JCO.1994.12.2.273

M3 - Article

VL - 12

SP - 273

EP - 278

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 2

ER -